Cytomegalovirus prophylaxis using low-dose valganciclovir in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation.
Po-Hsien LiCheng-Hsien LinYu-Hui LinTsung-Chih ChenChiann-Yi HsuChieh-Lin Jerry TengPublished in: Therapeutic advances in hematology (2021)
Low-dose valganciclovir prophylaxis could be an alternative to letermovir to prevent CMV infection in allo-HSCT, especially in resource-limited countries.